Interferon Gamma-1b

  title={Interferon Gamma-1b},
  author={Patricia A. Todd and Karen L. Goa},
SummarySynopsisChronic granulomatous disease is a group of rare x-linked or autosomal genetic disorders of the phagocytic NADPH oxidase system involved in host defence against various microorganisms. It is manifested by a common phenotype consisting of recurrent serious, life-threatening infection and granuloma formation. Following the finding that interferon gamma-1b (IFNγ-1b) can potentiate phagocyte activity in some other disease states as well as restoring defective phagocyte NADPH oxidase… 

Interferon γ-1b in chronic granulomatous disease and severe malignant osteopetrosis: a guide to its use in the USA

In the USA, subcutaneous interferon γ-1b (Actimmune®) is indicated to reduce the frequency and severity of serious infections associated with chronic granulomatous disease and delay the time to

Repurposing of gamma interferon via inhalation delivery

  • G. Smaldone
  • Medicine, Biology
    Advanced drug delivery reviews
  • 2018

Beyond antibiotics for pulmonary nontuberculous mycobacterial disease.

  • G. Waterer
  • Medicine, Biology
    Current opinion in pulmonary medicine
  • 2020
The authors' poor understanding of the immune deficit leading to NTM disease continues to hinder the development of highly effective therapies, and new approaches are promising but need significant validation before being considered viable therapeutic options.

Impaired immune response drives age-dependent severity of COVID-19

It is shown that the age-dependent increase of COVID-19 severity is caused by the disruption of a timely and well-coordinated innate and adaptive immune response due to impaired interferon (IFN) responses, and highly vulnerable individuals combining both risk factors, advanced age and an impaired type I IFN immunity, may greatly benefit from immunotherapy combining IFN-γ and IFn-λ.

Infectious Disease Therapy in the 1990s

It is important to establish a specific microbial diagnosis and initiate the appropriate antimicrobial therapy as rapidly as possible to establish and restore human immune responses against pathogenic and opportunistic microorganisms.

Evolutionary genetics evidence of an essential, nonredundant role of the IFN‐γ pathway in protective immunity

The integration of the population genetic data into a clinical framework demonstrates that the IFN‐γ pathway is essential and nonredundant in host defense, probably because of its role in protective immunity against mycobacteria.

IFN‐γ +874T/A polymorphism increases susceptibility to post‐traumatic osteomyelitis

Investigation of the potential link between IFN‐γ +874T/A polymorphism and risk of developing post‐traumatic osteomyelitis found that the frequency of mutant allele A was significantly higher in the patients than that in the healthy controls, and may contribute to the increased susceptibility to post‐ PTSD.

Host immune response against DENV and ZIKV infections

Dengue is a major public health concern, affecting almost 400 million people worldwide, with about 70% of the global burden of disease in Asia. Despite revised clinical classifications of dengue

IFN-γ as a Major Antiviral Therapeutic for Viral Epidemics, Including Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): A Clinically Forgotten but Potential Antiviral Cytokine and Non-Virus-Specific Antiviral as a New Antiviral Strategy

  • Biology, Medicine
    Journal of Clinical Review & Case Reports
  • 2020
Among the IFNs, IFN-γ is regarded as suitable and strongly recommended as a major antiviral agent, at least in high-risk patients who are infected by viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), when no vaccines or virus-specific antiviral therapeutics are available.



Partial Correction of the Phagocyte Defect in Patients with X-Linked Chronic Granulomatous Disease by Subcutaneous Interferon Gamma

The efficacy of interferon gamma, a physiologic activator of phagocytic-cell function, in the treatment of chronic granulomatous disease was examined, resulting in 5- to 10-fold increases in superoxide production by granulocytes and monocytes.

A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group.

For patients with chronic granulomatous disease, interferon gamma therapy is an effective and well-tolerated treatment that reduces the frequency of serious infections.

Recombinant human interferon-gamma as adjunct therapy for Aspergillus infection in a patient with chronic granulomatous disease.

This patient's treatment illustrates the usefulness of the single-photon emission computed tomography (SPECT) gallium scan for following pulmonary inflammatory lesions in the presence of fibrosis and indicates that rHuIFN-gamma may be of benefit to CGD patients with serious infections unresponsive to conventional therapy.

New perspectives in chronic granulomatous disease

Although phagocytes from patients with chronic granulomatous disease ingest microorganisms normally, killing is deficient because of the failure of a membrane-associated NADPH oxidase to produce superoxide and related toxic oxygen metabolites, which account for the morbidity and mortality associated with this disease.

Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood.

A partial correction in vivo of CGD patients' phagocyte defect with recombinant human interferon-gamma is demonstrated, suggesting that a significant proportion of patients with CGD will respond to rHuIFN-Gamma with augmentation of phagocytes microbicidal function.

Update on chronic granulomatous diseases of childhood. Immunotherapy and potential for gene therapy.

A 19-year-old black man presented with an autosomal recessive form of chronic granulomatous disease (CGD) of childhood (47-kd cytosol protein deficiency) as indicated by a failure of his stimulated neutrophils to consume oxygen or produce hydrogen peroxide and by defective in vitro killing of superoxide.

Molecular genetics of chronic granulomatous disease.

The recent genetic and biochemical findings provide an explanation for the consistent absence of the b-cytochrome spectrum in X-CGD, and establish this cytochrome as an essential component of the phagocyte oxidase.

In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae.

In vivo rIFN-gamma therapy improves the ability of CGD neutrophils to damage Aspergillus fumigatus hyphae in an in vitro assay, which was used to monitor neutrophil function before and during therapy.

Restoration of phagocyte function by interferon-gamma in X-linked chronic granulomatous disease occurs at the level of a progenitor cell.

Results indicate that INF-gamma can reprogram the myeloid progenitor cells to express a partially corrected phenotype, and this corrected phenotype is later expressed in daughter cells.

Recombinant interferon gamma augments phagocyte superoxide production and X-chronic granulomatous disease gene expression in X-linked variant chronic granulomatous disease.

Treatment of cultured monocytes from an IFN-gamma-responsive CGD patient increased the steady state level of RNA transcripts from the X-CGD gene from barely detectable up to approximately 5% of normal, and the cytochrome b spectrum remained undetectable.